Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
Mon Compte
No element in selection

Favoris
Établissements de santé
Contact Abonnez-vous aux actualités

1 result

Topics : Blood and lymphatic diseases
Active substance : romiplostim
Active substance : eltrombopag
Type : Chronic disease guide

Topic

Diseases and conditions (1)
Plus ...

Practice Guidelines and Other Guides (1)
Plus ...
- Chronic disease guide (1)

Date

Last five years (1)

Français (1)

Active substance

aciclovir (1)
alcool (1)
alemtuzumab (1)
allopurinol (1)
amoxicilline (1)
atovaquone (1)
azathioprine (1)
busulfan (1)
carbimazole (1)
chloroquine (1)
chlorpropamide (1)
ciclosporine (1)
ciprofloxacine (1)
cyclophosphamide (1)
danazol (1)
eltrombopag (1)
fer (1)
itraconazole (1)
leucine (1)
piroxicam (1)
posaconazole (1)
prednisolone (1)
rifampicine (1)
rituximab (1)
romiplostim (1)
sirolimus (1)
sulfasalazine (1)
tacrolimus (1)
valaciclovir (1)
voriconazole (1)

More filter Other Filter Icon

Other Filter Icon

Search Export

Première page
Page précédente
/ 1
Page suivante
Dernière page

Sorted by :Relevance

Title
Date

Acquired and inherited aplastic anemia

Chronic disease guide - Posted on 04/05/2024

Download guide

Add to my selection

Première page
Page précédente
/ 1
Page suivante
Dernière page
10 par pages

Follow us :

Advancing quality in the fields of health and social care services

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

3JQVK2ffmFHF4g3G